UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

The Lancet (British edition), 2014-08, Vol.384 (9944), p.665-673

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases

JNCI : Journal of the National Cancer Institute, 2014-07, Vol.106 (7), p.1

2014

Link zum Volltext

Verfügbarkeit prüfen

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2017-10, Vol.112, p.126-133

2017

Link zum Volltext

Verfügbarkeit prüfen

Superior Vena Cava Stent Migration into the Pulmonary Artery Causing Fatal Pulmonary Infarction

Cardiovascular and interventional radiology, 2011-02, Vol.34 (Suppl 2), p.198-201

2011

Link zum Volltext

Verfügbarkeit prüfen

Radiotherapy and cellular signalling

The lancet oncology, 2001-06, Vol.2 (6), p.366-370

2001

Link zum Volltext

Verfügbarkeit prüfen

Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice

Journal of clinical oncology, 2019-03, Vol.37 (8_suppl), p.147-147

2019

Link zum Volltext

Verfügbarkeit prüfen

Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9032-9032

2016

Link zum Volltext

Verfügbarkeit prüfen

Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9028-9028

2016

Link zum Volltext

Verfügbarkeit prüfen

Pegylated liposomal adriamycin: a review of current and future applications

Pharmaceutical Science & Technology Today, 1999-12, Vol.2 (12), p.473-477

1999

Link zum Volltext

Verfügbarkeit prüfen

Prostate Radiotherapy

Treatment Options in Urological Cancer, 2002, p.189-205

2002

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10030), p.1837-1846

2016

Link zum Volltext

Verfügbarkeit prüfen

Quality of life with second or third line nab -paclitaxel-based regimens in advanced non-small-cell lung cancer

Future oncology (London, England), 2020-04, Vol.16 (12), p.749-762

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9070-9070

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-15-05: Effects on outcome of concomitant neoadjuvant chemotherapy-trastuzumab compared with sequential neoadjuvant chemotherapy followed by post-operative trastuzumab

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P4-P4-15-05

2015

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer

Oncotarget, 2016-03, Vol.7 (11), p.13209-13220

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(21)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC)

Superior Vena Cava Stent Migration into the Pulmonary Artery Causing Fatal Pulmonary Infarction

Radiotherapy and cellular signalling

Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice

Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR

Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR)

Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC)

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Pegylated liposomal adriamycin: a review of current and future applications

Prostate Radiotherapy

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Quality of life with second or third line nab -paclitaxel-based regimens in advanced non-small-cell lung cancer

A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC

Abstract P4-15-05: Effects on outcome of concomitant neoadjuvant chemotherapy-trastuzumab compared with sequential neoadjuvant chemotherapy followed by post-operative trastuzumab

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer

Suchergebnisse filtern